S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
XBIT · XBiotech Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$1.99
-0.00
(-0.25%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.99
$1.99
$1.99
52-WEEK RANGE
$1.99
$1.91
$3.44
What's happening
- XBIT is down 0.25% today, trading at $1.99. — Live quote
- Volume today (295) is well below its 3-month average of 44,760. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $0.00 actual vs. $0.06 estimated (-100.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 4
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2021-12-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
XBIT
-15.48%
vs S&P 500
-28.26%
1-YEAR RETURN
XBIT
-18.55%
vs S&P 500
-33.11%
6-MONTH RETURN
XBIT
-16.87%
3-MONTH RETURN
XBIT
-9.82%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2020-04-26 (Q1 2020)
$0.00
Est. $0.06
MISS -100.0%
2020-01-26 (Q4 2019)
$14.59
Est. $-0.15
BEAT +9635.9%
2019-10-26 (Q3 2019)
$-0.15
Est. $-0.15
BEAT +2.0%
2019-07-26 (Q2 2019)
$-0.16
Est. $-0.15
MISS -4.6%
Valuation Measures & Ratios
Enterprise Value4-$50.5M
Forward P/E5—
PEG Ratio6-0.09
Price / Sales (TTM1)14.71
Price / Book70.55
EV4 / Revenue-12.60
EV4 / EBITDA-0.07
Profit Margin-820.45%
Operating Margin-860.10%
Return on Equity (ROE8)-31.62%
Return on Assets (ROA9)-30.29%
Avg Volume (3M)44,760
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short328,066
Change from Prior Settlement-5.49%
% of Float—
Days to Cover (Short Ratio)9.96
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-08-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -820.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -18.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on XBIT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$6.1M | -$6.3M | -$6.0M | -$6.3M | -$13.6M | -$7.9M | -$15.0M | -$10.9M |
| Net income | -$6.7M | -$5.5M | -$6.0M | -$1.8M | -$10.9M | -$5.0M | -$13.0M | -$10.0M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| EPS (basic) | $-0.22 | $-0.18 | $-0.20 | $-0.06 | $-0.36 | $-0.16 | $-0.43 | $-0.33 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $133.7M | $139.8M | $150.1M | $172.4M | $178.7M | $181.9M | $199.1M | $209.9M |
| Total liabilities | $5.2M | $4.8M | $9.7M | $5.3M | $5.6M | $7.2M | $16.8M | $17.7M |
| Stockholders' equity | $128.5M | $135.0M | $140.3M | $167.1M | $173.1M | $174.7M | $182.3M | $192.1M |
| Total current assets | $111.2M | $117.0M | $127.0M | $149.0M | $154.9M | $157.7M | $174.6M | $185.0M |
| Total current liabilities | $3.4M | $3.0M | $7.9M | $3.6M | $3.9M | $5.4M | $15.1M | $16.0M |
| Cash & equivalents | $109.5M | $115.5M | $125.6M | $147.4M | $152.9M | $155.9M | $172.7M | $183.1M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | $450.0K | $480.0K | $480.0K | $700.0K | $730.0K |
| Property, plant & equipment | $22.5M | $22.8M | $23.1M | $23.5M | $23.8M | $24.2M | $24.5M | $24.8M |
| Accounts payable | $1.1M | $857.0K | $1.5M | $1.0M | $1.4M | $1.1M | $2.2M | $1.5M |
| Accrued liabilities | $2.2M | $2.0M | $6.3M | $2.4M | $2.4M | $4.3M | $2.6M | $4.5M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $277.1M | $276.9M | $276.7M | $276.6M | $276.5M | $276.4M | $273.1M | $272.4M |
| Retained earnings | -$148.6M | -$141.9M | -$136.4M | -$109.5M | -$103.5M | -$101.7M | -$90.8M | -$80.3M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.5M | -$9.0M | -$23.0M | -$4.3M | -$6.0M | -$6.7M | -$6.5M | -$5.8M |
| Investing cash flow | -$4.0K | $9.0K | -$34.0K | -$110.0K | -$51.0K | -$94.0K | -$84.0K | -$338.0K |
| Financing cash flow | $0 | $0 | $0 | $0 | $0 | -$10.2M | $283.0K | $64.0K |
| Free cash flow | -$4.5M | -$9.0M | -$23.0M | -$4.4M | -$6.0M | -$6.8M | -$6.6M | -$6.2M |
| Capital expenditures | $0 | $0 | $34.0K | $110.0K | $51.0K | $94.0K | $84.0K | $338.0K |
| Share-based compensation | $172.0K | $172.0K | $162.0K | $24.0K | $107.0K | $3.3M | $628.0K | $365.0K |
| Deferred income taxes | — | — | $5.0K | — | — | — | $0 | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | $246.0K | -$678.0K | $492.0K | -$385.0K | $330.0K | -$1.1M | $653.0K | -$200.0K |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Gross profit | — | — | $0 | $3.4M | $12.6M |
| Operating income | -$55.7M | -$42.5M | -$37.5M | -$34.5M | -$25.1M |
| Net income | -$45.5M | -$38.5M | -$24.6M | -$32.9M | -$17.4M |
| EPS (diluted) | $-1.49 | $-1.26 | $-0.81 | $-1.08 | $-0.58 |
| EPS (basic) | $-1.49 | $-1.26 | $-0.81 | $-1.08 | $-0.58 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $150.1M | $199.1M | $226.6M | $246.1M | $275.2M |
| Total liabilities | $9.7M | $16.8M | $7.8M | $5.7M | $5.8M |
| Stockholders' equity | $140.3M | $182.3M | $218.8M | $240.4M | $269.4M |
| Total current assets | $127.0M | $174.6M | $201.7M | $219.8M | $246.9M |
| Total current liabilities | $7.9M | $15.1M | $6.1M | $4.1M | $3.5M |
| Cash & equivalents | $125.6M | $172.7M | $200.0M | $157.3M | $237.0M |
| Marketable securities (current) | — | — | $0 | $60.2M | $0 |
| Accounts receivable | — | — | — | — | $0 |
| Property, plant & equipment | $23.1M | $24.5M | $24.9M | $26.3M | $28.3M |
| Accounts payable | $1.5M | $2.2M | $2.5M | $2.4M | $2.1M |
| Accrued liabilities | $6.3M | $2.6M | $3.5M | $1.6M | $1.4M |
| Deferred revenue (current) | — | — | — | — | — |
| Common stock & paid-in capital | $276.7M | $273.1M | $271.2M | $267.3M | $262.3M |
| Retained earnings | -$136.4M | -$90.8M | -$52.3M | -$27.7M | $5.2M |
| Accumulated other comprehensive income (loss) | — | — | $0 | $826.0K | $2.0M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$39.9M | -$31.0M | -$18.7M | -$14.8M | $69.4M |
| Investing cash flow | -$289.0K | -$1.3M | $61.5M | -$63.9M | -$3.5M |
| Financing cash flow | -$10.2M | $10.4M | -$9.0K | $0 | -$67.0M |
| Free cash flow | -$40.2M | -$32.3M | -$19.1M | -$15.4M | $65.9M |
| Capital expenditures | $289.0K | $1.3M | $362.0K | $585.0K | $3.5M |
| Share-based compensation | $3.6M | $1.8M | $3.3M | $5.1M | $4.5M |
| Deferred income taxes | $5.0K | $0 | -$59.0K | -$816.0K | $1.4M |
| Change in accounts receivable | — | — | — | $0 | -$4.1M |
| Change in accounts payable | -$688.0K | -$364.0K | $91.0K | $357.0K | -$514.0K |
| Dividends paid | — | — | — | $0 | $75.0M |
| Share repurchases | — | $0 | $14.0K | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding XBIT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2021-10-07 to 2021-12-16
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| MCKENZIE W THORPE | Director | Option exercise | 2021-12-16 | 250,000 |
| SIMARD JOHN | Chief Executive Officer | Open market sale | 2021-10-18 | 33,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:44 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-05-14 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-03-13 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2025-12-09 | 8-K | 2025-12-05 | View on SEC.gov → |
| 2025-11-12 | 10-Q | 2025-09-30 | View on SEC.gov → |
| 2025-11-12 | 4 | 2025-10-01 | View on SEC.gov → |
| 2025-11-12 | 4 | 2025-10-01 | View on SEC.gov → |
| 2025-11-12 | 4 | 2025-10-01 | View on SEC.gov → |
| 2025-11-12 | 4 | 2025-10-01 | View on SEC.gov → |
| 2025-10-03 | 8-K | 2025-10-01 | View on SEC.gov → |
| 2025-09-02 | 8-K | 2025-08-29 | View on SEC.gov → |
| 2025-08-13 | 10-Q | 2025-06-30 | View on SEC.gov → |
Recent news
Headlines about XBIT (XBiotech Inc.). Links open the publisher — we don’t host full articles.
-
XBIT Nov 2026 2.500 call (XBIT261120C00002500) stock historical prices and data
Yahoo Finance Australia · 2026-10-20 -
XBIT Nov 2026 5.000 call (XBIT261120C00005000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-20 -
XBIT Nov 2026 2.500 call (XBIT261120C00002500) Stock Historical Prices & Data
Yahoo! Finance Canada · 2026-10-20 -
XBIT Nov 2026 2.500 call (XBIT261120C00002500) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
XBiotech’s cancer drug meets trial survival target By Investing.com
Investing.com India · 2026-10-19 -
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
Yahoo · 2026-10-19 -
XBiotech Inc. Announces Positive Phase II Final Efficacy Results From Investigator-Sponsored TASKIN Trial In Refractory Metastatic Colorectal Cancer
www.marketscreener.com · 2026-10-19 -
XBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Ar
Benzinga · 2026-10-19
No headlines in this category right now — try “All”.